These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9835420)

  • 1. Hollow fibre bioreactors: an alternative to murine ascites for small scale (<1 gram) monoclonal antibody production.
    Lipman NS; Jackson LR
    Res Immunol; 1998; 149(6):571-6. PubMed ID: 9835420
    [No Abstract]   [Full Text] [Related]  

  • 2. Considerations for in vitro monoclonal antibody production.
    Peterson NC
    Res Immunol; 1998; 149(6):553-7. PubMed ID: 9835417
    [No Abstract]   [Full Text] [Related]  

  • 3. In vivo and in vitro production of monoclonal antibodies: current possibilities and future perspectives. Discussion.
    Hendriksen CF; de Leeuw WA
    Res Immunol; 1998; 149(6):611-20. PubMed ID: 9835427
    [No Abstract]   [Full Text] [Related]  

  • 4. Membrane-based cell culture technologies: a scientifically and economically satisfactory alternative to malignant ascites production for monoclonal antibodies.
    Marx U
    Res Immunol; 1998; 149(6):557-9. PubMed ID: 9835418
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal antibody production: problems and solutions.
    Falkenberg FW
    Res Immunol; 1998; 149(6):542-7. PubMed ID: 9835415
    [No Abstract]   [Full Text] [Related]  

  • 6. Membrane-based cell culture systems--an alternative to in vivo production of monoclonal antibodies.
    Nagel A; Koch S; Valley U; Emmrich F; Marx U
    Dev Biol Stand; 1999; 101():57-64. PubMed ID: 10566776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro production of monoclonal antibodies: current possibilities and future perspectives. Introduction.
    de Geus B; Hendriksen CF
    Res Immunol; 1998; 149(6):533-4. PubMed ID: 9835413
    [No Abstract]   [Full Text] [Related]  

  • 8. Production of monoclonal antibodies in the miniPERM bioreactor: comparison with other hybridoma culture methods.
    Falkenberg FW
    Res Immunol; 1998; 149(6):560-70. PubMed ID: 9835419
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of oxygen carriers for increasing the production of monoclonal antibodies from hollow fibre bioreactors.
    Shi Y; Sardonini CA; Goffe RA
    Res Immunol; 1998; 149(6):576-87. PubMed ID: 9835421
    [No Abstract]   [Full Text] [Related]  

  • 10. Production of monoclonal antibodies by the ascites method in laboratory animals.
    Hendriksen CF; de Leeuw W
    Res Immunol; 1998; 149(6):535-42. PubMed ID: 9835414
    [No Abstract]   [Full Text] [Related]  

  • 11. In vivo and in vitro production of monoclonal antibodies. Bioreactors vs immune ascites.
    Marx U; Merz W
    Methods Mol Biol; 1995; 45():169-76. PubMed ID: 7550678
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of small to moderate scale in vitro monoclonal antibody production via the use of the i-MAb gas-permeable bag system.
    Lipski LA; Witzleb MP; Reddington GM; Reddington JJ
    Res Immunol; 1998; 149(6):547-52. PubMed ID: 9835416
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of hollow fiber bioreactors as an alternative to murine ascites production for small scale monoclonal antibody production.
    Jackson LR; Trudel LJ; Fox JG; Lipman NS
    J Immunol Methods; 1996 Feb; 189(2):217-31. PubMed ID: 8613673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of monoclonal antibody supernatant and ascites fluid.
    Yokoyama WM
    Curr Protoc Mol Biol; 2001 May; Chapter 11():Unit11.10. PubMed ID: 18265068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of the chemical composition of cell culture material on the growth and antibody production of hybridoma cells.
    Heilmann K; Groth T; Behrsing O; Albrecht W; Schossig M; Lendlein A; Micheel B
    J Biotechnol; 2005 Feb; 115(3):291-301. PubMed ID: 15639091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple hollow-fiber bioreactor for the "in-house" production of monoclonal antibodies.
    Goodall M
    Methods Mol Biol; 1998; 80():39-56. PubMed ID: 9664362
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal antibody production in hollow fiber bioreactors using serum-free medium.
    Heifetz AH; Braatz JA; Wolfe RA; Barry RM; Miller DA; Solomon BA
    Biotechniques; 1989 Feb; 7(2):192-9. PubMed ID: 2629847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of monoclonal antibody supernatant and ascites fluid.
    Yokoyama WM
    Curr Protoc Mol Biol; 2008 Jul; Chapter 11():Unit 11.10. PubMed ID: 18633992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody production in murine ascites. I. Clinical and pathologic features.
    Jackson LR; Trudel LJ; Fox JG; Lipman NS
    Lab Anim Sci; 1999 Feb; 49(1):70-80. PubMed ID: 10090098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody production in murine ascites. II. Production characteristics.
    Jackson LR; Trudel LJ; Fox JG; Lipman NS
    Lab Anim Sci; 1999 Feb; 49(1):81-6. PubMed ID: 10090099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.